Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 2016 10 01; 380(2):494-504.

View in: PubMed

subject areas

Acrylamides
Aniline Compounds
Animals
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Apoptosis
Carcinoma, Non-Small-Cell Lung
Cell Line, Tumor
Cell Proliferation
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
ErbB Receptors
Erlotinib Hydrochloride
Female
G1 Phase Cell Cycle Checkpoints
Gene Amplification
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms
Mice, Nude
Molecular Targeted Therapy
Mutation
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-met
Pyrazoles
Pyridines
Pyrimidines
RNA Interference
Signal Transduction
Time Factors
Transfection
Tumor Burden
Xenograft Model Antitumor Assays

authors with profiles

Ravi Salgia